Stocks Buzz: FireEye (NASDAQ:FEYE), 1-800-Flowers.com Inc. (NASDAQ:FLWS), Ophthotech Corporation (NASDAQ:OPHT), Ligand Pharmaceuticals Incorporated (NASDAQ:LGND), Linn Energy, LLC (NASDAQ:LINE)

On 27 Januay, FireEye, Inc. (NASDAQ:FEYE) and Viewfinity announced an integration of Viewfinitiy’s advanced endpoint protection solution with both the FireEye® Threat Analytics Platform™ (TAP™), a cloud-based security analytics platform, and the FireEye AX series, a group of forensic analysis platforms. FireEye, Inc. (NASDAQ:FEYE) has 1.00% insider ownership while its institutional ownership stands at 61.40%. In last trading activity company’s stock closed at $34.51.

On 2 February, 1-800-Flowers.com Inc. (NASDAQ:FLWS) reported total net revenues from continuing operations of $534.3 million for its fiscal 2015 second quarter ended December 28, 2014, compared with revenues from continuing operations of $266.3 million in the prior year period. 1-800-Flowers.com Inc. (NASDAQ:FLWS) in last trading activity moved up 7.17% to close at $9.57. Company weekly performance is 32.92% while its quarterly performance stands at 19.48%. 1-800-Flowers.com Inc. (NASDAQ:FLWS) is 2.79% away from its 52 week high.

Ophthotech Corporation (NASDAQ:OPHT) was downgraded by equities researchers at JPMorgan Chase & Co. from an “overweight” rating to a “neutral” rating in a research report issued on Monday. They currently have a $60.00 price objective on the stock. JPMorgan Chase & Co.’s price objective would indicate a potential upside of 6.67% from the stock’s previous close. The analysts noted that the move was a valuation call. On last trading day Ophthotech Corporation (NASDAQ:OPHT) moved down -0.76% to close at $49.69. Its volatility for the week is 6.18% while volatility for the month is 5.34%. Ophthotech Corporation (NASDAQ:OPHT) monthly performance is 6.70%.

On 3 February, Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) announced the signing of a license agreement with Sermonix Pharmaceuticals LLC for the development and commercialization of oral lasofoxifene in the United States and additional territories. Under the terms of the agreement, Ligand has received an undisclosed initial payment, and is entitled to receive up to $45 million in potential regulatory and commercial milestone payments and tiered royalties of 6% to 10% on future net sales. Lasofoxifene is an estrogen partial agonist for the treatment of osteoporosis and other diseases. Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) has 2.20% insider ownership while its institutional ownership stands at 94.10%. In last trading activity company’s stock closed at $53.90.

Linn Energy, LLC (NASDAQ:LINE) and LinnCo, LLC announced that management will host a conference call on Thursday, February 19, 2015, at 10 a.m. Central (11 a.m. Eastern) to discuss the Company’s fourth quarter and full-year 2014 results. On last trading day Linn Energy, LLC (NASDAQ:LINE) fell -2.02% to close at $11.63. Its volatility for the week is 7.35% while volatility for the month is 6.55%. LINE’s sales growth for past 5 years was 10.20% and its EPS growth for past 5 years was -19.20%. Linn Energy, LLC (NASDAQ:LINE) monthly performance is 5.25%.

Leave a Reply

Your email address will not be published. Required fields are marked *

*